DDInter1840 DDInter425
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Fosaprepitant
Fosaprepitant {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Septic shock
Septic shock {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Cobimetinib
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Fosaprepitant (Compound) and Fosaprepitant may lead to a major life threatening interaction when taken with Cobimetinib
Trabectedin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Trabectedin (Compound) causes Septic shock (Side Effect) and Septic shock (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may lead to a major life threatening interaction when taken with Cobimetinib